

## **Curriculum vitae Jonas Larsson MD PhD**

### **Personal data**

Born in Malmö, Sweden July 9, 1971  
Married, two daughters

### **Professional preparation**

Medical School, Lund University, 1991-1999, M.D. granted Jan. 1999

Graduate School, Lund University, Dep of Molecular Medicine and Gene Therapy, 1996-2002, Ph.D. granted Nov. 2002

Postdoctoral fellow, Harvard Medical School, Center for Regenerative Medicine, Jan 2004 – Feb. 2006

### **Appointments**

Current appointment: Group Leader, Molecular Medicine and Gene Therapy, Lund Strategic Research Center for Stem Cell Biology and Cell Therapy, Lund University Sweden since March 2006.

Earlier positions held:

1999-2000 Medical officer, Lund University Hospital, Sweden  
2003 Research fellow, Lund University, Sweden

### **Teaching and supervision**

PhD supervision:

Ulrika Blank, Lund University, 2000-2006 (cosupervisor)  
Christine Glanz, Lund University, 2006 -present

Supervision of Master Degree Students:

Gudrun Valdemarsdottir 1997-1998  
Wiaam Badn 1999- 2000  
Hildur Helgadottir 2000  
Maj-Linda Selenica 2001  
Göran Karlsson 2002-2003  
Marie Aspling, Harvard Medical School 2004-present

Teacher in cell biology for medical students two semesters during 2002

### **Research evaluation**

Assigned reviewer for scientific journals:

“Blood”, “Experimental Hematology”, “European Journal of Hematology” and “Stem Cells”.

## **Invited speaker**

September 01 – I.C.P seminar series, Bruxelles, Belgium. Inv. by M. Vikkula  
December 01 – NIH seminar series, Bethesda, MD, USA. Inv. by A. Kulkarni  
Maj 03 – Biogen Inc., Cambridge, MA, USA. Inv. by Kam Cheung  
Februari 06 – ESH/AACR conference, Cascais, Portugal. Inv. by George Daley  
March 06 – Karolinska Institute , Stockholm. Inv. by Nils Göran Larsson  
September 06 – ISEH annual meeting, Minneapolis, USA. Inv. by ISEH

## **Awards**

2003 “Tegger” price Malmö, Sweden  
2003 Wennergren postdoctoral award (returned)  
2004 EMBO postdoctoral award (2 years)  
2006 SSMF postdoctoral award

## **Personal references**

Stefan Karlsson, Professor, Lund University.  
Molecular Medicine and Gene Therapy, BMC A12, 221 84 Lund. Phone: 046-2220577, E-mail: [stefan.karlsson@med.lu.se](mailto:stefan.karlsson@med.lu.se)

David T. Scadden, Professor, Harvard Medical School; Co-director, Harvard Stem Cell Institute; Director, MGH Center for Regenerative Medicine.  
Massachusetts General Hospital, CPZN-4265A, 185 Cambridge Street, Boston, MA 02114, USA. Phone: +1-617-726-5615 E-mail: [scadden.david@mgh.harvard.edu](mailto:scadden.david@mgh.harvard.edu)

Sten Eirik Jacobsen, Professor, Lund University, Director, Lund Strategic Center for Stem Cell Research.  
Hematopoietic Stem Cell Laboratory, BMC B10, 221 84 Lund. Phone: 046-2224852, E-mail: [sten.jacobsen@med.lu.se](mailto:sten.jacobsen@med.lu.se)

## Publications for Jonas Larsson

- 1: Larsson J, Scadden D. Homing and mobilization of hematopoietic stem cells. **Nat Med**. 2006, invited review pending publication.
- 2: Blank U, Karlsson, G, Moody J, Utsugisawa T, Magnusson M, Singbrant S, Larsson J, Karlsson S. Smad7 promotes self-renewal of hematopoietic stem cells in vivo. 2006. **Blood**, in press
- 3: Larsson J, Scadden D. Nervous activity in a stem cell niche. **Cell**. 2006 Jan 27;124(2):253-5
- 4: Leveen P, Carlsen M, Makowska A, Oddsson S, Larsson J, Goumans MJ, Cilio CM, Karlsson S. TGF-beta type II receptor-deficient thymocytes develop normally but demonstrate increased CD8+ proliferation in vivo. **Blood**. 2005 Dec 15;106(13):4234-40.
- 5: Larsson J, Karlsson S. The role of Smad signaling in hematopoiesis. **Oncogene**. 2005 Aug 29;24(37):5676-92.
- 6: Chuva de Sousa Lopes SM, van den Driesche S, Carvalho RL, Larsson J, Eggen B, Surani MA, Mummery CL. Altered primordial germ cell migration in the absence of transforming growth factor beta signaling via ALK5. **Dev Biol**. 2005 Aug 1;284(1):194-203.
- 7: Larsson J, Blank U, Klintman J, Magnusson M, Karlsson S. Quiescence of hematopoietic stem cells and maintenance of the stem cell pool is not dependent on TGF-beta signaling in vivo. **Exp Hematol**. 2005 May;33(5):592-6.
- 8: Karlsson G, Liu Y, Larsson J, Goumans MJ, Lee JS, Thorgeirsson SS, Ringner M, Karlsson S. Gene expression profiling demonstrates that TGF-beta1 signals exclusively through receptor complexes involving Alk5 and identifies targets of TGF-beta signaling. **Physiol Genomics**. 2005 May 11;21(3):396-403.
- 9: Carvalho RL, Jonker L, Goumans MJ, Larsson J, Bouwman P, Karlsson S, Dijke PT, Arthur HM, Mummery CL. Defective paracrine signalling by TGF-beta in yolk sac vasculature of endoglin mutant mice: a paradigm for hereditary haemorrhagic telangiectasia. **Development**. 2004 Dec;131(24):6237-47.
- 10: Chuva de Sousa Lopes S, Feijen A, Korving J, Korchynsky O, ten Dijke P, Lyons K, Goldschmeding R, Larsson J, Karlsson S, Doevendans P, Mummery C. Connective tissue growth factor expression and Smad signaling during mouse heart development and myocardial infarction. **Dev Dyn**. 2004 Nov;231(3):542-50.
- 11: Oe S, Lemmer ER, Conner EA, Factor VM, Leveen P, Larsson J, Karlsson S, Thorgeirsson SS. Intact signaling by transforming growth factor beta is not required for termination of liver regeneration in mice. **Hepatology**. 2004 Nov;40(5):1098-105.
- 12: Larsson J, Blank U, Helgadottir H, Bjornsson JM, Ehinger M, Goumans MJ, Fan X, Leveen P, Karlsson S. TGF-beta signaling-deficient hematopoietic stem cells have normal self-renewal and regenerative ability in vivo despite increased proliferative capacity in vitro. **Blood**. 2003 Nov 1;102(9):3129-35.
- 13: Goumans MJ, Valdimarsdottir G, Itoh S, Lebrin F, Larsson J, Mummery C, Karlsson S, ten Dijke P. Activin Receptor-like Kinase (ALK)-1 is an Antagonistic Mediator of Lateral TGFbeta/ALK-5 Signaling. **Mol Cell**. 2003 Oct;12(4):817-28.

14: Bjornsson JM, Larsson N, Brun AC, Magnusson M, Andersson E, Lundstrom P, Larsson J, Repetowska E, Ehinger M, Humphries RK, Karlsson S. Reduced proliferative capacity of hematopoietic stem cells deficient in Hoxb3 and Hoxb4. **Mol Cell Biol.** 2003 Jun;23(11):3872-83.

15: Leveen P, Larsson J, Ehinger M, Cilio CM, Sundler M, Sjostrand LJ, Holmdahl R, Karlsson S. Induced disruption of the transforming growth factor beta type II receptor gene in mice causes a lethal inflammatory disorder that is transplantable. **Blood.** 2002 Jul 15;100(2):560-8.

16: Fan X, Valdimarsdottir G, Larsson J, Brun A, Magnusson M, Jacobsen SE, ten Dijke P, Karlsson S. Transient disruption of autocrine TGF-beta signaling leads to enhanced survival and proliferation potential in single primitive human hemopoietic progenitor cells. **J Immunol.** 2002 Jan 15;168(2):755-62.

17: Larsson J, Goumans MJ, Sjostrand LJ, van Rooijen MA, Ward D, Leveen P, Xu X, ten Dijke P, Mummery CL, Karlsson S. Abnormal angiogenesis but intact hematopoietic potential in TGF-beta type I receptor-deficient mice. **EMBO J.** 2001 Apr 2;20(7):1663-73.

Manuscripts, submitted or in preparation:

Larsson J, Ali N, Aspling M, Hacohen N, Scadden DT. A forward genetic screen identifies regulators of growth and survival in primitive human CD34+ hematopoietic cells. 2006. In preparation.

Larsson J, Aspling M, McClatchey A, Scadden DT. A critical role for the tumor suppressor neurofibromatosis 2 in regulation of hematopoietic stem cell self-renewal. 2006. In preparation.

Magnusson M, Brun ACM, Miyake N, Larsson J, Ehinger M, Björnsson J-M, Wutz A, Sigvardsson M, Karlsson S. Distinct hematopoietic cell fates are regulated by graded expression of HoxA10. 2006. Submitted to Genes Dev.

Honjo Y, Nagineni CH, Larsson J, Nandula SR, Hooks JJ, Chan CC, Karlsson S, Kulkarni AB. Retinal detachment and Cataracts in mice with neuron-specific TGF-beta signaling deficiency. 2006. Submitted to Nat. Neurosci.